

Press Release  
15 February 2022 11:00:00 CET



## Newbury on business focus and strategy (Video)

**Newbury Pharmaceuticals' CEO has joined an interview with Västra Hamnen Corporate Finance where the topic was Newbury's choice of business focus and its strategies for growth.**

In the interview, CEO Lars Minor explains the reason for the company's focus, its pipeline as well as already registered products, and its strategic strengths in light of the ambitious growth targets. In the clip, Lars Minor is seen in conversation with Alf Riple, Chief Analyst at Västra Hamnen Corporate Finance.

The video clip is available [here](#).

**For more information, contact:**

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

### **About Newbury Pharmaceuticals**

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.

### **Attachments**

---

[Newbury on business focus and strategy \(Video\)](#)